CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
PRIME-ADC develops a novel method for creating antibody drug conjugates using peptide-based microreactors. This approach enhances the precision and stability of drug conjugation while eliminating copper toxicity, aiming to improve cancer treatment efficiency and reduce environmental impact.
Antibody drug conjugates are among the most promising targeted cancer therapies, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs.
Yet, more than 80% of ADC candidates fail to progress beyond early clinical stages. A key reason lies in current conjugation chemistries: lysine- and cysteine-based methods yield heterogeneous products with unstable linkages, poor pharmacokinetics, and high manufacturing inefficiencies, wasting up to 50% of material.
Copper-catal…
TEL AVIV UNIVERSITY
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, ROMA RM
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
